The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.

Sabashini K RamchandJoy N TsaiHang LeeGrace Sassana-KhadkaMackenzie JordanSavannah RyanBenjamin Z Leder

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2023)

These results suggest that after one year of denosumab, one year of alendronate is better able to maintain the inhibition of bone remodeling and BMD gains than raloxifene.

Keyphrases

bone mineral density
postmenopausal women
giant cell
clinical trial
body composition
study protocol
randomized controlled trial
phase iii
bone loss